213Bi与225Ac标记低分子量化合物用于前列腺癌放射配体治疗的临床前评价
研究基于177Lu-L1骨架合成α粒子发射体213Bi-L1与225Ac-L1,在PSMA阳性前列腺癌异种移植模型中评价其安全性及细胞杀伤效果。225Ac-L1表现出活性依赖的肿瘤生长抑制和微转移模型生存获益,主要脱靶放射毒性见于肾和肝,估计最大耐受活度约1 MBq/kg。
要点
- 213Bi-L1与225Ac-L1在PSMA阳性细胞中显示特异性摄取和细胞杀伤。
- 225Ac-L1在PSMA阳性皮下及微转移模型中显示活性依赖的疗效。
- 225Ac-L1的脱靶放射毒性主要见于肾和肝,估计最大耐受活度约1 MBq/kg。
核心结论
- 225Ac-L1表现出活性依赖的疗效且治疗相关器官放射毒性最小,是有望进一步临床评估的治疗药物。
研究设计与样本
- 临床前研究,评价213Bi-L1和225Ac-L1的放射化学合成、细胞摄取、细胞杀伤及生物分布。
- 在PSMA阳性人源皮下及微转移模型中确定225Ac-L1的疗效。
- 评估225Ac-L1给药后8周亚急性毒性和1年慢性毒性。
- 利用生物分布数据和α相机成像确定225Ac-L1的吸收辐射剂量。
主要发现
- 213Bi-L1和225Ac-L1在PSMA阳性细胞中显示特异性细胞摄取和细胞杀伤。
- 213Bi-L1和225Ac-L1的生物分布显示放射性在PSMA阳性病灶中特异性摄取。
- 225Ac-L1在PSMA阳性侧腹肿瘤模型中显示活性依赖的特异性肿瘤生长抑制。
- 与177Lu-L1相比,225Ac-L1在微转移模型中显示生存获益增加。
- 225Ac-L1的活性递增急性和慢性毒性研究显示脱靶放射毒性主要位于肾和肝。
关键数值与推荐
- 225Ac-L1估计最大耐受活度约1 MBq/kg。
临床怎么用
- 225Ac-L1作为PSMA靶向α粒子放射配体治疗候选药物,需进一步临床评估。
- 临床转化时需关注肾和肝的脱靶放射毒性及最大耐受活度约1 MBq/kg。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical therapy is a new option for patients with advanced prostate cancer refractory to other treatments. Previously, we synthesized a β-particle-emitting low-molecular-weight compound, 177Lu-L1 which demonstrated reduced off-target effects in a xenograft model of prostate cancer. Here, we leveraged that scaffold to synthesize α-particle-emitting analogs of L1, 213Bi-L1 and 225Ac-L1, to evaluate their safety and cell kill effect in PSMA-positive (+) xenograft models. Methods: The radiochemical synthesis, cell uptake, cell kill, and biodistribution of 213Bi-L1 and 225Ac-L1 were evaluated. The efficacy of 225Ac-L1 was determined in human PSMA+ subcutaneous and micrometastatic models. Subacute toxicity at 8 wk and chronic toxicity at 1 y after administration were evaluated for 225Ac-L1. The absorbed radiation dose of 225Ac-L1 was determined using the biodistribution data and α-camera imaging. Results:213Bi- and 225Ac-L1 demonstrated specific cell uptake and cell kill in PSMA+ cells. The biodistribution of 213Bi-L1 and 225Ac-L1 revealed specific uptake of radioactivity within PSMA+ lesions. Treatment studies of 225Ac-L1 demonstrated activity-dependent, specific inhibition of tumor growth in the PSMA+ flank tumor model. 225Ac-L1 also showed an increased survival benefit in the micrometastatic model compared with 177Lu-L1. Activity-escalated acute and chronic toxicity studies of 225Ac-L1 revealed off-target radiotoxicity, mainly in kidneys and liver. The estimated maximum tolerated activity was about 1 MBq/kg. α-Camera imaging of 225Ac-L1 revealed high renal cortical accumulation at 2 h followed by fast clearance at 24 h. Conclusion:225Ac-L1 demonstrated activity-dependent efficacy with minimal treatment-related organ radiotoxicity. 225Ac-L1 is a promising therapeutic for further clinical evaluation.
引用
- Banerjee SR, Lisok A, Minn I, et al. Preclinical Evaluation of 213Bi- and 225Ac-Labeled Low-Molecular-Weight Compounds for Radiopharmaceutical Therapy of Prostate Cancer. J Nucl Med. 2020. PMID: 33246975. doi:10.2967/jnumed.120.256388
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。